Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

about

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

Item

http://www.wikidata.org/entity/Q52582168

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@en

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@nl

type

Item

label

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@en

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@nl

prefLabel

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@en

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@nl

P1476

Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.

@en

P2093

Ashley P Barry

http://www.w3.org/2001/XMLSchema#string

Bethany Powell Gray

http://www.w3.org/2001/XMLSchema#string

Bruce A Sullenger

http://www.w3.org/2001/XMLSchema#string

Christina Kratschmer

http://www.w3.org/2001/XMLSchema#string

Douglas P Ahrens

http://www.w3.org/2001/XMLSchema#string

Linsley Kelly

http://www.w3.org/2001/XMLSchema#string

Matthew Levy

http://www.w3.org/2001/XMLSchema#string

P2860

From selection hits to clinical leads: progress in aptamer discovery

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

In vitro selection of RNA molecules that bind specific ligands

Antibody therapy of cancer

RNA aptamers as reversible antagonists of coagulation factor IXa.

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass.

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.

Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.

A general RNA motif for cellular transfection.

P304

4761-4766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1717705115

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29666232

http://www.w3.org/2001/XMLSchema#string

P932

5939073

http://www.w3.org/2001/XMLSchema#string